N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply

Affiliations

¹ University of Munich, Munich, Germany. Electronic address: juergen.behr@med.uni-muenchen.de.
² Université Paris Diderot, Paris, France.
³ Royal Brompton Hospital, London, UK.
⁴ F Hoffmann-La Roche Ltd, Basel, Switzerland.
⁵ University of Turin, Turin, Italy.

Comment

Jürgen Behr et al. Lancet Respir Med. 2017 Jan.

. 2017 Jan;5(1):e3.

doi: 10.1016/S2213-2600(16)30418-0.

¹ University of Munich, Munich, Germany. Electronic address: juergen.behr@med.uni-muenchen.de.
² Université Paris Diderot, Paris, France.
³ Royal Brompton Hospital, London, UK.
⁴ F Hoffmann-La Roche Ltd, Basel, Switzerland.
⁵ University of Turin, Turin, Italy.

No abstract available

Comment on

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J, Bendstrup E, Crestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C. Behr J, et al. Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. Lancet Respir Med. 2016. PMID: 27161257 Clinical Trial.
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
Raghu G, Noth I, Martinez F. Raghu G, et al. Lancet Respir Med. 2017 Jan;5(1):e1-e2. doi: 10.1016/S2213-2600(16)30327-7. Lancet Respir Med. 2017. PMID: 28000596 No abstract available.